Related Experiment Videos
Multifocal Castleman disease in pediatrics: case report
Mariana Baserga1, Melissa Rosin, Michael Schoen
1Department of Pediatrics, Children's Hospital of Orange County, Orange, CA, USA.
Journal of Pediatric Hematology/Oncology
|December 14, 2005
Summary
Multicentric Castleman disease (MCD) is a rare disorder. This case study details a 4-year-old girl successfully treated for MCD with combination chemotherapy, showing disease remission.
Area of Science:
- Pediatric Hematology Oncology
- Rare Lymphoproliferative Disorders
- Castleman Disease Pathogenesis
Background:
- Multicentric Castleman disease (MCD) is a rare, complex lymphoproliferative disorder with unknown etiology.
- Pediatric MCD is exceptionally uncommon, presenting diagnostic and therapeutic challenges.
- Early recognition and prompt treatment are crucial for managing MCD's severity and prognosis.
Observation:
- A 4-year-old female presented with prolonged fever, hypoalbuminemia, thrombocytopenia, anasarca, and widespread lymphadenopathy.
- Diagnostic workup was extensive, delaying definitive diagnosis for several weeks.
- A lymph node biopsy confirmed multicentric Castleman disease, mixed-type.
Findings:
- The patient received combination chemotherapy including cyclophosphamide, vincristine, doxorubicin, and prednisone.
- Treatment was well-tolerated with no significant adverse events.
- The patient achieved complete disease remission and remained disease-free at 36 months follow-up.
Implications:
- This case highlights the importance of considering MCD in pediatric patients with unexplained systemic symptoms.
- Combination chemotherapy demonstrated efficacy and tolerability in a pediatric MCD case.
- Successful treatment suggests a favorable prognosis with aggressive management in pediatric MCD.